Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first

MLA

John A. Storwick, et al. “Checkpoint Inhibitor Immunotherapy Induced Inflammatory Arthritis Secondary to Nivolumab and Ipilimumab: A Pediatric First.” Pediatric Rheumatology Online Journal, vol. 22, no. 1, Apr. 2024, pp. 1–4. EBSCOhost, https://doi.org/10.1186/s12969-024-00983-3.

APA

John A. Storwick, Herman Tam, Daniel G. Rosenbaum, & Kristin Houghton. (2024). Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first. Pediatric Rheumatology Online Journal, 22(1), 1–4. https://doi.org/10.1186/s12969-024-00983-3

Chicago

John A. Storwick, Herman Tam, Daniel G. Rosenbaum, and Kristin Houghton. 2024. “Checkpoint Inhibitor Immunotherapy Induced Inflammatory Arthritis Secondary to Nivolumab and Ipilimumab: A Pediatric First.” Pediatric Rheumatology Online Journal 22 (1): 1–4. doi:10.1186/s12969-024-00983-3.